Skip to main content
Premium Trial:

Request an Annual Quote

Ambit, Cephalon Pen Kinase Drug-Discovery, Development Alliance

NEW YORK (GenomeWeb News) — Ambit Biosciences today said it will combine its KinomeScan-driven discovery technology with Cephalon's chemistry and discovery and development chops to help develop kinase inhibitors.
Terms of the deal call for Ambit to screen a “large” library of Cephalon’s kinase-focused compounds to generate “nearly a million data points,” Ambit said. In return, Cephalon will pay Ambit $18 million in an up-front fee to access its KinomeScan technology.
The companies will also partner in two programs targeting undisclosed kinases. Terms of those deals give Ambit the responsibility for delivering clinical candidates that Cephalon will further develop in exchange for $232.5 million in additional milestones to Ambit, as well as royalties.
Ambit will also use Cephalon library compounds to discover and develop products that are effective inhibitors of certain undisclosed kinases, the company said.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.